Biovica International AB (publ) (BIOVIC-B.ST)
SEK 1.62
(-8.47%)
SEK 1.62
(-8.47%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 6.87 Million SEK | -2720.42% |
| 2022 | 4.61 Million SEK | -1.05% |
| 2021 | 4.66 Million SEK | -11.46% |
| 2020 | 5.27 Million SEK | -37.9% |
| 2019 | 8.48 Million SEK | -1.75% |
| 2018 | 8.63 Million SEK | 4.02% |
| 2017 | 8.3 Million SEK | 63.06% |
| 2016 | 5.09 Million SEK | -25.14% |
| 2015 | 6.8 Million SEK | 64.9% |
| 2014 | 4.12 Million SEK | 14.47% |
| 2013 | 3.6 Million SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 1.55 Million SEK | 103.76% |
| 2023 FY | -120.98 Million SEK | -2720.42% |
| 2023 Q3 | 772 Thousand SEK | -70.81% |
| 2023 Q1 | 2.2 Million SEK | 83.32% |
| 2023 Q2 | 2.64 Million SEK | 19.74% |
| 2023 Q4 | -41.47 Million SEK | -5472.8% |
| 2022 Q2 | 1.11 Million SEK | 28.8% |
| 2022 FY | 4.61 Million SEK | -1.05% |
| 2022 Q4 | 1.2 Million SEK | -15.5% |
| 2022 Q3 | 1.42 Million SEK | 27.55% |
| 2022 Q1 | 868 Thousand SEK | -50.0% |
| 2021 Q2 | 848 Thousand SEK | -27.4% |
| 2021 FY | 4.66 Million SEK | -11.46% |
| 2021 Q1 | 1.16 Million SEK | 42.27% |
| 2021 Q4 | 1.73 Million SEK | 90.14% |
| 2021 Q3 | 913 Thousand SEK | 7.67% |
| 2020 FY | 5.27 Million SEK | -37.9% |
| 2020 Q2 | 895 Thousand SEK | -54.06% |
| 2020 Q3 | 1.6 Million SEK | 79.66% |
| 2020 Q4 | 821 Thousand SEK | -48.94% |
| 2020 Q1 | 1.94 Million SEK | -39.58% |
| 2019 Q2 | 3.15 Million SEK | 106.22% |
| 2019 Q3 | 2.17 Million SEK | -31.04% |
| 2019 Q1 | 1.52 Million SEK | -54.24% |
| 2019 FY | 8.48 Million SEK | -1.75% |
| 2019 Q4 | 3.22 Million SEK | 48.37% |
| 2018 Q1 | 1.88 Million SEK | -29.74% |
| 2018 FY | 8.63 Million SEK | 4.02% |
| 2018 Q4 | 3.33 Million SEK | 62.64% |
| 2018 Q3 | 2.05 Million SEK | 50.96% |
| 2018 Q2 | 1.36 Million SEK | -27.85% |
| 2017 Q2 | 1.67 Million SEK | -27.31% |
| 2017 Q1 | 2.3 Million SEK | 62.58% |
| 2017 FY | 8.3 Million SEK | 63.06% |
| 2017 Q4 | 2.68 Million SEK | 64.0% |
| 2017 Q3 | 1.63 Million SEK | -2.44% |
| 2016 Q3 | 1.4 Million SEK | 50.91% |
| 2016 FY | 5.09 Million SEK | -25.14% |
| 2016 Q4 | 1.41 Million SEK | 1.21% |
| 2016 Q2 | 929 Thousand SEK | -30.72% |
| 2016 Q1 | 1.34 Million SEK | -9.88% |
| 2015 Q4 | 1.48 Million SEK | 0.0% |
| 2015 Q2 | 1.91 Million SEK | 0.0% |
| 2015 Q1 | 1.91 Million SEK | 0.0% |
| 2015 FY | 6.8 Million SEK | 64.9% |
| 2015 Q3 | 1.48 Million SEK | -22.22% |
| 2014 FY | 4.12 Million SEK | 14.47% |
| 2013 FY | 3.6 Million SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -160.68 Million SEK | 104.28% |
| Ziccum AB (publ) | -23.28 Million SEK | 129.533% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 346.31 Million SEK | 98.014% |
| Sprint Bioscience AB (publ) | 41.78 Million SEK | 83.543% |
| Mendus AB (publ) | 28.48 Million SEK | 75.859% |
| Genovis AB (publ.) | 54 Million SEK | 87.265% |
| Intervacc AB (publ) | -13.79 Million SEK | 149.855% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 2.17 Million SEK | -216.766% |
| Active Biotech AB (publ) | -1.67 Million SEK | 510.567% |
| Magle Chemoswed Holding AB (publ) | 9.96 Million SEK | 30.975% |
| Bio-Works Technologies AB (publ) | 26.82 Million SEK | 74.36% |
| Aptahem AB (publ) | 2.63 Million SEK | -161.418% |
| Vicore Pharma Holding AB (publ) | -3.42 Million SEK | 301.023% |
| Kancera AB (publ) | -1.96 Million SEK | 449.975% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -8831.169% |
| Fluicell AB (publ) | 1.73 Million SEK | -295.685% |
| Saniona AB (publ) | 11.78 Million SEK | 41.626% |
| Lipigon Pharmaceuticals AB (publ) | -5.11 Million SEK | 234.395% |
| Spago Nanomedical AB (publ) | -23.28 Million SEK | 129.537% |
| AcouSort AB (publ) | 8.38 Million SEK | 18.024% |
| Xintela AB (publ) | 78 Thousand SEK | -8716.667% |
| Abliva AB (publ) | -35.66 Million SEK | 119.283% |
| Egetis Therapeutics AB (publ) | -146.9 Million SEK | 104.681% |
| Karolinska Development AB (publ) | 2.8 Million SEK | -144.995% |
| OncoZenge AB (publ) | 3000.00 SEK | -229133.333% |
| Amniotics AB (publ) | -1.93 Million SEK | 456.321% |
| 2cureX AB (publ) | -37.48 Million SEK | 118.345% |
| CombiGene AB (publ) | -21.29 Million SEK | 132.301% |
| Asarina Pharma AB (publ) | -423 Thousand SEK | 1725.768% |
| Calliditas Therapeutics AB (publ) | 1.12 Billion SEK | 99.391% |
| Camurus AB (publ) | 1.58 Billion SEK | 99.565% |
| Corline Biomedical AB | 28.38 Million SEK | 75.768% |
| IRLAB Therapeutics AB (publ) | -122.73 Million SEK | 105.603% |
| Isofol Medical AB (publ) | -34.41 Million SEK | 119.983% |
| I-Tech AB | 27.56 Million SEK | 75.053% |
| Hansa Biopharma AB (publ) | 70.95 Million SEK | 90.307% |
| Cyxone AB (publ) | 2.61 Million SEK | -163.386% |
| ExpreS2ion Biotech Holding AB (publ) | 3.4 Million SEK | -102.086% |
| Biosergen AB | -456 Thousand SEK | 1608.114% |
| Cantargia AB (publ) | -3.45 Million SEK | 299.276% |
| NextCell Pharma AB | -43.74 Million SEK | 115.72% |
| Xspray Pharma AB (publ) | -9.19 Million SEK | 174.799% |
| Elicera Therapeutics AB (publ) | 11.21 Million SEK | 38.698% |
| Nanologica AB (publ) | -76 Thousand SEK | 9148.684% |
| SynAct Pharma AB | -778 Thousand SEK | 983.933% |
| Annexin Pharmaceuticals AB (publ) | -193 Thousand SEK | 3663.212% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | -12.92 Million SEK | 153.219% |
| Lipum AB (publ) | 53 Thousand SEK | -12875.472% |
| BioInvent International AB (publ) | 71.46 Million SEK | 90.377% |
| Alzinova AB (publ) | 19.87 Million SEK | 65.397% |
| Oncopeptides AB (publ) | 36.29 Million SEK | 81.055% |
| Pila Pharma AB (publ) | 1.46 Million SEK | -370.055% |
| Guard Therapeutics International AB (publ) | -15 Thousand SEK | 45946.667% |
| Scandinavian ChemoTech AB (publ) | 1.65 Million SEK | -314.777% |
| Simris Alg AB (publ) | 2 Million SEK | -242.651% |
| Diamyd Medical AB (publ) | -3.58 Million SEK | 292.095% |
| Xbrane Biopharma AB (publ) | 35.38 Million SEK | 80.567% |
| Ascelia Pharma AB (publ) | -1.04 Million SEK | 755.577% |
| Diagonal Bio AB (publ) | 3.13 Million SEK | -119.502% |